To complement the prostate-specific antigen (PSA) in PCa diagnostic screening programs, urine N- and O-glycoproteomic profiling from PCa and benign prostatic hyperplasia (BPH) were compared. This evidence concerns the gene PROS1 and benign prostatic hyperplasia.